• Osteoporosis guideline update recommends romosozumab for women at high fracture risk

    1 month ago - By Healio

    The Endocrine Society updated its osteoporosis clinical practice guideline to include recommendations for romosozumab, noting that the monthly injection therapy is an “effective option” for postmenopausal women at high risk for fracture, according to a society press release.
    In announcing the updated recommendations, the guideline committee also noted that romosozumab , a humanized monoclonal antibody that targets sclerostin, is not indicated for all postmenopausal women at high fracture risk, stating that women with a history of cardiovascular disease are not
    Read more ...